Details

Identification of potential human targets for epigallocatechin gallate through a novel protein binding site screening approach
ID Hirci, Jernej (Author), ID Škufca, Sandra (Author), ID Kunej, Tanja (Author), ID Janežič, Dušanka (Author), ID Konc, Janez (Author)

.pdfPDF - Presentation file, Download (1,74 MB)
MD5: 48766354F8BC168677CA21F7F0FA0444
URLURL - Source URL, Visit https://link.springer.com/article/10.1007/s00894-025-06410-y This link opens in a new window

Abstract
Context Epigallocatechin-3-gallate (EGCG), a compound found in green tea, is known for its anticancer properties, although its specific protein targets remain largely undefined. In this study, we identified EGCG targets across the human proteome using a novel protein binding site screening approach. Among the 20 most likely predicted targets, six proteins—KRAS, FXa, MMP1, PLA2G2A, Hb, and CDK2—had been experimentally validated in previous studies. Fourteen additional proteins, including five kinases, were newly predicted as potential targets, all of which are implicated in cancer development and may mediate EGCG’s anticancer effects. Enrichment analysis revealed KEGG pathways associated with cancer, with KRAS and PIM1 appearing as key nodes. These findings, which align with previous experimental research, offer new insights into the molecular mechanisms of EGCG and its potential role in modulating cancer-related pathways. Methods An approach was devised to screen EGCG with 36,532 human protein binding sites using the ProBiS-Dock algorithm and the ProBiS-Dock database. Network and enrichment analyses with Cytoscape and StringApp identified protein interactions and KEGG pathways, revealing potential anticancer mechanisms of EGCG.

Language:English
Keywords:epigallocatechin-3-gallate, ProBiS-Dock algorithm, ProBiS-Dock database, inverse molecular docking, target protein prediction
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:BF - Biotechnical Faculty
FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:12 str.
Numbering:Vol. 31, iss. 7, art. 189
PID:20.500.12556/RUL-169968 This link opens in a new window
UDC:577
ISSN on article:0948-5023
DOI:10.1007/s00894-025-06410-y This link opens in a new window
COBISS.SI-ID:239493635 This link opens in a new window
Publication date in RUL:27.06.2025
Views:553
Downloads:205
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of molecular modeling
Publisher:Springer Nature
ISSN:0948-5023
COBISS.SI-ID:2506772 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:biokemija, rak, epigalokatehin galat

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0220
Name:Primerjalna genomika in genomska biodiverziteta

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0142
Name:COGEVAB: nova računalniška orodja na molekularni skali za študij vpliva genskih variacij na vezavo zdravil

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0209
Name:Orodja za inovativno oblikovanje zdravil

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4414
Name:ProBiS-Fold pristop za določanje vezavnih mest za celoten strukturni človeški proteom pri odkrivanju zdravil

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L7-8269
Name:Novi pristopi za boljša biološka zdravila

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back